Benralizumab

FASENRA

Interleukin-5 Receptor alpha-directed Cytolytic Antibody

NADAC/unit N/A

No Shortage Tier 1: 51.7% PA Req: 250.2%

Covered Lives

Market Intelligence

2025-10-22 Class II Recall: ASTRAZENECA PHARMACEUTICALS

Explore in the Ecosystem

rxsaver.aiCompare prices for Benralizumab drfinder.aiFind doctors who prescribe Benralizumab rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Benralizumab

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.